This is the authors' abstract. We don't add key points for this paper.
The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activity against Aspergillus, but over the last few years there has been an explosion of newer agents and reformulations of older antifungals. Exploration has also begun with immunotherapy, with use of cytokines and granulocyte transfusions alone or in combination with antifungal therapy. This review will detail the available in vitro, in vivo, and clinical experience with the newer antifungal and immunomodulatory therapies in development for treatment of invasive aspergillosis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Steinbach et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: